Integrated filling for the Financial result 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 1.2 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sattva Sukun Lifecare Ltd announced its audited financial results for FY25 alongside board meeting outcomes. Standalone revenue from operations rose to ₹526.30 lakh from ₹355.33 lakh in FY24 (~48% growth), while profit after tax jumped to ₹249.03 lakh from ₹119.19 lakh (~109% growth). Operating cash flow turned positive at ₹52.62 lakh compared to a negative ₹276.77 lakh last year. The company also approved a Rights Issue of 48 crore equity shares at ₹1 each (ratio 5:2) to raise up to ₹48 crore, with the record date set for 9th May 2025. Two Independent Directors resigned citing personal reasons, and Mr. Gaurav Surendra Nair was appointed as a Non-Executive Non-Independent Director. The statutory auditor (SSRV & Associates) issued an unmodified opinion on both standalone and consolidated results.
The strong growth in revenue and more than doubling of profits is positive for shareholders, though the EPS diluted dropped to ₹0.40 from ₹0.50 due to increased share count. The ₹48 crore rights issue will significantly dilute existing shareholders by ~250%, potentially pressuring the stock price in the short term, but brings in capital for future growth.